Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Solid cancers after allogeneic hematopoietic cell transplantation.

Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O, Travis LB, Travis WD, Flowers ME, Friedman DL, Horowitz MM, Wingard JR, Deeg HJ.

Blood. 2009 Jan 29;113(5):1175-83. doi: 10.1182/blood-2008-05-158782. Epub 2008 Oct 29.

2.

New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia.

Socié G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB, Sullivan KM, Rowlings PA, Kingma DW, Banks PM, Travis WD, Witherspoon RP, Sanders J, Jaffe ES, Horowitz MM.

J Clin Oncol. 2000 Jan;18(2):348-57.

PMID:
10637249
3.

Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning.

Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM, Bolwell B, Wingard JR, Socie G.

Blood. 2011 Jan 6;117(1):316-22. doi: 10.1182/blood-2010-07-294629. Epub 2010 Oct 6.

5.

Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis.

Shimada K, Yokozawa T, Atsuta Y, Kohno A, Maruyama F, Yano K, Taji H, Kitaori K, Goto S, Iida H, Morishima Y, Kodera Y, Naoe T, Morishita Y.

Bone Marrow Transplant. 2005 Jul;36(2):115-21.

PMID:
15908969
6.

Second solid cancers after allogeneic hematopoietic stem cell transplantation.

Gallagher G, Forrest DL.

Cancer. 2007 Jan 1;109(1):84-92.

7.

Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.

Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.

Biol Blood Marrow Transplant. 2008 Jun;14(6):658-63. doi: 10.1016/j.bbmt.2008.03.008.

8.

Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group.

Kolb HJ, Socié G, Duell T, Van Lint MT, Tichelli A, Apperley JF, Nekolla E, Ljungman P, Jacobsen N, van Weel M, Wick R, Weiss M, Prentice HG.

Ann Intern Med. 1999 Nov 16;131(10):738-44.

PMID:
10577296
9.

Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.

Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.

Haematologica. 2002 Jan;87(1):52-8.

11.

Solid cancers after bone marrow transplantation.

Bhatia S, Louie AD, Bhatia R, O'Donnell MR, Fung H, Kashyap A, Krishnan A, Molina A, Nademanee A, Niland JC, Parker PA, Snyder DS, Spielberger R, Stein A, Forman SJ.

J Clin Oncol. 2001 Jan 15;19(2):464-71.

PMID:
11208840
12.

Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease.

Atsuta Y, Suzuki R, Yamashita T, Fukuda T, Miyamura K, Taniguchi S, Iida H, Uchida T, Ikegame K, Takahashi S, Kato K, Kawa K, Nagamura-Inoue T, Morishima Y, Sakamaki H, Kodera Y; Japan Society for Hematopoietic Cell Transplantation.

Ann Oncol. 2014 Feb;25(2):435-41. doi: 10.1093/annonc/mdt558. Epub 2014 Jan 7.

13.

Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.

Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H, Kodera Y, Okamoto S, Kanda Y, Sao H, Asai O, Nakai K, Maruta A, Kishi K, Furukawa T, Atsuta Y, Yamamoto K, Tanaka J, Takahashi S.

Bone Marrow Transplant. 2005 Nov;36(10):867-72.

PMID:
16113659
15.

Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation.

Hasegawa W, Pond GR, Rifkind JT, Messner HA, Lau A, Daly AS, Kiss TL, Kotchetkova N, Galal A, Lipton JH.

Bone Marrow Transplant. 2005 Jan;35(1):51-5.

PMID:
15516939
16.

Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study.

Cohen A, Rovelli A, Merlo DF, van Lint MT, Lanino E, Bresters D, Ceppi M, Bocchini V, Tichelli A, Socié G.

J Clin Oncol. 2007 Jun 10;25(17):2449-54.

17.

[Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].

Faber E, Koza V, Vítek A, Mayer J, Sedlácek P, Zák P, Zapletalová J, Benesová K, Krejcová H, Steinerová K, Maresová I, Cetkovský P.

Vnitr Lek. 2006 Dec;52(12):1172-80. Czech.

PMID:
17299910
18.

Oral malignancies following HSCT: graft versus host disease and other risk factors.

Demarosi F, Lodi G, Carrassi A, Soligo D, Sardella A.

Oral Oncol. 2005 Oct;41(9):865-77. Epub 2005 Apr 14. Review.

PMID:
16084755
19.

Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria.

Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Körholz D, Pape H, Dunst J, Kahn T, Willers R, Engel B, Dirksen U, Kramm C, Nürnberger W, Heyll A, Ladenstein R, Gadner H, Jürgens H, Go el U.

Ann Oncol. 2000 Nov;11(11):1451-62. Review.

20.

A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.

Conrad R, Remberger M, Cederlund K, Ringdén O, Barkholt L.

Haematologica. 2008 Feb;93(2):265-72. doi: 10.3324/haematol.11672.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk